Kringle Pharma announces that the last subject has completed the follow-up period after dosing in the Phase I/II study of recombinant human HGF for acute spinal cord injury.

Kringle Pharma announces that the last subject has completed the follow-up period after dosing in the Phase I/II study of recombinant human HGF for acute spinal cord injury.